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Hepatocellular carcinoma (HCC) is the fifth most commonmalignancy worldwide with a poor
prognosis and limited therapeutic options. To aid the development of novel immunological
interventions, we studied the breadth, frequency, and tumor-infiltration of naturally occurring
CD81 T-cell responses targeting several tumor-associated antigens (TAA). We used overlapping
peptides spanning the entire alpha-fetoprotein (AFP), glypican-3 (GPC-3), melanoma-
associated gene-A1 (MAGE-A1) and New York-esophageal squamous cell carcinoma-1 (NY-
ESO-1) proteins and major-histocompatibility-complex-class-I-tetramers specific for epitopes
ofMAGE-A1 andNY-ESO-1 to analyze TAA-specific CD81 T-cell responses in a large cohort of
HCCpatients. After nonspecific expansion in vitro, we detected interferon-c (IFN-c)-producing
CD81 T cells specific for all four TAA in the periphery as well as in liver and tumor tissue. These
CD81 T-cell responses displayed clear immunodominance patterns within each TAA, but no
consistent hierarchy was observed between different TAA. Importantly, the response breadth
was highest in early-stage HCC and associated with patient survival. After antigen-specific
expansion, TAA-specific CD81 T cells were detectable by tetramer staining but impaired in
their ability to produce IFN-c. Furthermore, regulatory T cells (Treg) were increased in HCC
lesions. Depletion of Treg from cultures improved TAA-specific CD8
1 T-cell proliferation but
did not restore IFN-c-production. Conclusion: Naturally occurring TAA-specific CD81 T-cell
responses are present in patients with HCC and therefore constitute part of the normal T-cell
repertoire. Moreover, the presence of these responses correlates with patient survival. However,
the observation of impaired IFN-c production suggests that the efficacy of such responses is
functionally limited. These findings support the development of strategies that aim to enhance
the total TAA-specific CD81 T-cell response by therapeutic boosting and/or specificity diversifi-
cation. However, further research will be required to help unlock the full potential of TAA-
specific CD81 T-cell responses. (HEPATOLOGY 2014;59:1415-1426)
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options remain limited. Consequently, HCC patients suffer
from a high mortality rate.1 New therapies for HCC are
therefore urgently required. Immunotherapy is a promising
approach for the treatment of HCC.2 The rationale for
immunological intervention is based on the presence of high
numbers of tumor-infiltrating T cells in HCC tissue,3 the
correlation between the density of lymphocytic infiltrates in
HCC lesions and prognosis,4 and, most importantly, the
finding that adoptive immunotherapy with interleukin
(IL)22/anti-CD3-stimulated autologous lymphocytes lowers
postsurgical recurrence rates in humans.5 The central effectors
in this scenario are CD81 T cells that recognize tumor-
associated antigens (TAA) and kill tumor cells. TAA comprise
a range of self-derived proteins rendered immunogenic in
tumors either by mutation or aberrant expression.6 A variety
of different TAA can spontaneously induce CD81 T-cell
responses in HCC patients; these include a-fetoprotein
(AFP), glypican-3 (GPC-3), melanoma-associated gene-A1
(MAGE-A1), and New York-esophageal squamous cell
carcinoma-1 (NY-ESO-1).7-10 In addition, TAA-specific
responses can also be boosted in vivo in HCC patients by
dendritic cell-based vaccination with tumor lysate.11
The identification of TAA that are frequently recog-
nized by CD81 T cells in HCC patients could provide
important insights into the choice of appropriate targets
for immunotherapy. However, most previous studies
focused on single TAA, thus precluding within-patient
comparisons. Indeed, to our knowledge, only two previ-
ous studies have compared CD81 T-cell responses to
different TAA in HCC patients.12,13 Moreover, these
studies were limited to analyses of previously described
epitopes restricted by human leukocyte antigen (HLA)-
A*02 and HLA-A*24, respectively.
In this study we used overlapping peptides spanning
the entire sequences of AFP, GPC-3, MAGE-A1, and
NY-ESO-1 in a cohort of 96 HCC patients to evaluate
naturally occurring CD81 T-cell responses against four
major HCC-associated TAA irrespective of HLA restric-
tion. Our results provide the first comprehensive view of
TAA-specific CD81 T-cell responses in this setting with
attendant implications for therapeutic vaccine design.
Materials and Methods
Patients and Samples. Patients were recruited
from the Department of Internal Medicine and the
Department of Surgery at University Hospital Freiburg
and from the Department of General and Transplant
Surgery at University Hospital Heidelberg. The study
was conducted in accordance with the principles of the
Declaration of Helsinki under approval and guidance
of local Ethics Committees. Ethylenediaminetetraace-
tate (EDTA)-anticoagulated blood, pieces of liver biop-
sies performed for diagnostic purposes, and samples
from liver resections were obtained with written
informed consent in all cases. Four-digit HLA-geno-
typing was performed using standard techniques.
Experimental Procedures. Detailed information
on the experimental procedures can be found in the
Supporting Online Material.
Statistical Analysis. Statistical analyses were per-
formed two-tailed to a significance level of 95% using
GraphPad Prism v. 5 (GraphPad Software, La Jolla,
CA). The tests used are indicated in the figure legends.
All clinical data were obtained from the date of enroll-
ment. Diagnosis of liver cirrhosis was based on patient
charts and sonography, with the addition of histology
where available. However, since histology was only
available for a fraction of patients, liver cirrhosis can-
not be completely excluded in all of the patients classi-
fied as noncirrhotic. Progression-free survival (PFS)
was calculated as the number of days between the suc-
cessful therapeutic intervention closest to enrollment
and radiological evidence of disease progression. If
patients were lost to follow-up prior to disease progres-
sion, data were censored at the date of the last exami-
nation. For the Cox proportional hazards model, IBM
SPSS Statistics v. 21 (IBM, Armonk, NY) was used.
Lines indicate median values unless stated otherwise.
Results
Study Cohort. A total of 96 HCC patients and 15
controls, including two healthy donors, two patients
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with acute, and 11 patients with chronic hepatitis were
recruited for this study. Cohort characteristics are
shown in Table 1 and detailed information on HCC
patients is available in Supporting Table 2. Most
patients had HCC related to chronic alcohol abuse
(35.4%), followed by hepatitis C virus infection
(HCV; 24.0%), hepatitis B virus infection (HBV;
9.4%), and nonalcoholic steatohepatitis (NASH;
9.4%). For 17 patients (17.7%) no underlying condi-
tion could be identified. Most patients (57.3%) were
treatment-na€ıve at the time of enrollment, pretreated
patients had most commonly received transarterial che-
moembolization (TACE; 17.7% of all patients). The
patients were staged according to the Barcelona Clinic
Liver Cancer (BCLC) classification.14 Most patients
had early (BCLC A, 28.1%) or intermediate HCC
(BCLC B, 36.5%).
Detection of TAA-Specific CD81 T-Cell Responses
in Patients With HCC. TAA-specific CD81 T-cell
responses were analyzed by stimulating antigen-
unspecifically expanded CD81 T cells derived from
peripheral blood mononuclear cells (PBMC) with
overlapping peptides spanning the entire length of
AFP, GPC-3, MAGE-A1, and NY-ESO-1 and then
evaluated for the production of interferon-c (IFN-c)
by intracellular cytokine staining and flow cytometry.
Representative data are shown in Fig. 1A. TAA-
specific responses were detectable in PBMC of 49
patients (51.6%), most of whom recognized one,
two, or three peptides (22, 11, and 10 patients,
respectively) while only six patients had responses to
four or more different peptides (Fig. 1B). Notably,
we were able to detect TAA-specific CD81 T-cell
responses to all four antigens tested. Only one
response, specific for an AFP-derived peptide, was
detected in one individual within the control group.
Thus, TAA-specific CD81 T-cell responses were sig-
nificantly more frequently detectable in patients with
HCC. Next, we analyzed the association between tumor
stage and the presence of TAA-specific CD81 T cells (Fig.
1C). Significantly more responses were detectable in
patients with very early HCC (BCLC 0) compared to
patients with later stages (BCLC A, B, or C). There were
no differences with regard to response magnitude (%IFN-
c1/CD81 T cells; data not shown). Since locoregional
Table 1. Patient Characteristics
HCC Melanoma Control Control (Treg Analysis)
Number of patients 96 8 15 61
Gender % male 84.4 37.5 60 62.3
% female 14.6 62.5 40 37.7
Age [y] median 68 46 38 37
range 45-85 35-80 23-69 22-73
Serum AFP [ng/ml] median 11.5 n.d. n.d. n.d.
range 1.4-60,500
BCLC stage (%) 0 13.5 n.d. n.d. n.d.
A 28.1
B 36.5
C 16.7
D 4.2
unknown 1.0
Liver cirrhosis (%) 72.9 n.d. 26.7 0
Cause of liver disease (%) ethanol 35.4 n.d. 6.7 0
HCV 24.0 40 27.9
cryptogenic 17.7 13.3 8.2
HBV 9.4 6.7 14.7
NASH 9.4 0 1.6
other 4.2 20 1.6
healthy 0 13.3 46.0
Treatment prior to inclusion (%) none 57.3 n.d. n.d. n.d.
TACE 17.7
TACE1resection 6.3
resection 6.3
TACE1RFTA 4.2
TACE1sorafenib 1.0
PEI 1.0
RFTA 1.0
unknown 5.2
Barcelona Clinic Liver Cancer (BCLC) stages: 0, very early; A, early; B, intermediate; C, advanced; D, terminal. HCV: hepatitis C virus. HBV: hepatitis B virus.
NASH: nonalcoholic steatohepatitis. TACE: transarterial chemoembolization. RFTA: radiofrequency thermal ablation. PEI: percutaneous ethanol injection. n.d.: not
determined.
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therapy, especially radiofrequency thermal ablation
(RFTA) has been described to induce TAA-specific CD81
T-cell responses,15,16 we also tested whether we could
observe an effect in patients who had undergone locore-
gional therapy prior to enrollment. We focused on patients
pretreated with TACE since they represented the most size-
able population within the pretreated subgroup of the
cohort. Indeed, patients previously treated with TACE had
significantly more TAA-specific CD81 T-cell responses
than patients who were treatment-na€ıve at the time of
enrollment (Fig. 1D).
TAA-Specific CD81 T Cells Infiltrate the Tumor
But Do Not Accumulate There. To extend these
observations, we analyzed TAA-specific CD81 T-cell
responses in tumor and surrounding liver tissue.
Paired samples of CD81 T cells derived from differ-
ent sites were available as follows: PBMC and intra-
hepatic lymphocytes (IHL), 10 patients; PBMC and
tumor-infiltrating lymphocytes (TIL), 17 patients;
IHL and TIL, six patients. Samples from all three
sites were available for simultaneous analysis from
five patients undergoing liver resection. Representa-
tive data of one of these patients are shown in Fig.
2A. Even though we were able to detect TAA-
specific CD81 T-cell responses in all compartments
analyzed, a pairwise comparison revealed that TAA-
specific CD81 T-cell responses were significantly
weaker in CD81 T cells derived from TIL com-
pared to those derived from IHL (Fig. 2B). Simi-
larly, TAA-specific responses in CD81 T cells
derived from TIL were weaker than those derived
from PBMC, although this trend did not reach sta-
tistical significance. Of note, the number of
responses did not differ between the individual com-
partments (data not shown).
Fig. 1. Detection of tumor-associated antigen-specific CD81 T cells in patients with HCC. CD81 T cells were isolated from PBMC by magnetic
bead enrichment, antigen-unspecifically expanded and stimulated with overlapping peptides spanning the entire length of AFP, GPC-3, MAGE-A1,
and NY-ESO-1. Production of IFN-c was determined by flow cytometry. (A) Representative dotplots showing production of IFN-c in response to
the indicated peptides in one HCC patient. Plots were gated on live lymphocytes, numbers indicate %IFN-c1/CD81 T cells. The upper panel
shows the unstimulated control. (B) Pie charts comparing the number of CD81 T-cell responses to the indicated number of peptides in PBMC of
95 HCC patients and 15 controls. The comparison was performed by Mann-Whitney U-test. (C) The number of individual peptides recognized is
shown for HCC patients according to BCLC tumor stage (0, very early; A, early; B, intermediate; C, advanced; D, terminal). Each dot represents
one patient. Values were compared by Kruskal-Wallis test. (D) The number of individual peptides recognized within 55 patients that were
treatment-na€ıve at the time of inclusion is compared to that of 17 patients that had undergone TACE prior to enrollment. Each dot represents
one patient. Values were compared by Mann-Whitney U-test.
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Presence of TAA-Specific CD81 T-Cell Responses
Is Associated With Patient Survival. For 76
patients, sufficient data from follow-up examinations
at the University Hospital Freiburg was available to
enable evaluation of PFS (Supporting Table 2). Of
these 76 patients, 41 (53.9%) had detectable TAA-
specific CD81 T-cell responses. Patients with TAA-
specific responses had a significantly greater median
PFS of 279 days compared to 177 days in patients
without responses (Fig. 3). Next, we stratified patients
according to the number of TAA that triggered CD81
T-cell responses (Supporting Fig. 1). Indeed, there was
a correlation between PFS and the number of TAA
recognized. Thus, patient survival appeared to be
linked to the occurrence of TAA-specific CD81 T-cell
responses and their spread across multiple TAA. How-
ever, this may be confounded by the observed enrich-
ment of responses in patients with early stage HCC
and/or by their association with prior treatments. To
address these issues, we established a proportional haz-
ards model for 73 patients with complete datasets
(Supporting Table 2). Indeed, this model indicated
that BCLC stage, liver cirrhosis, and the recognition of
one or two TAA were all independent prognostic fac-
tors for PFS (Table 2). Furthermore, resection at the
start of PFS (as compared to TACE) and pretreatment
with the combination of TACE and RFTA were found
as significant contributors. Of note, due to the small
number of patients with responses to three or four
TAA, the contribution of these subgroups failed to
reach statistical significance while still showing a trend
for improved survival over patients without responses
(Supporting Fig. 1).
Hierarchy of CD81 T-Cell Responses to Different
Tumor Antigens. Next, we compared the hierarchy
of CD81 T-cell responses to the individual antigens.
Most TAA-specific CD81 T-cell responses were
observed against AFP and GPC-3, followed by NY-
ESO-1 and MAGE-A1 (Fig. 4A). We also found a sig-
nificant heterogeneity between the four TAA with
Fig. 2. Tumor-infiltration of TAA-specific CD81 T cells. CD81 T cells were isolated from PBMC, IHL, and TIL and then evaluated as described
in the legend to Fig. 1. (A) Representative dotplots showing the production of IFN-c in response to the peptide GPC-3 36 in one HCC patient in
PBMC, IHL, and TIL. Numbers indicate %IFN-c1/CD81 T cells. The upper panels show the unstimulated control. (B) Pairwise comparison of
response magnitude (%IFN-c1/CD81 T cells) in the different compartments. Each dot represents one peptide-specific CD81 T-cell response. Wil-
coxon signed rank test was used.
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respect to the CD81 T-cell response magnitude (Fig.
4B). The strongest responses were directed against
MAGE-A1 followed by GPC-3, NY-ESO-1, and AFP.
As 27 of the 96 patients had responses to more than
one antigen, we also asked whether there were any pre-
dominant combinations of TAA-specific CD81 T-cell
responses (Fig. 4C). However, no clear combinatorial
associations were apparent.
Identification of Immunodominant Regions and
Epitopes. To determine immunodominance profiles
within the individual TAA, we assessed the distribution
of CD81 T-cell responses across each protein sequence
(Fig. 4D). In all four TAA, we identified single domi-
nant regions that were targeted by CD81 T cells. For
AFP, this was a previously unmapped region at the N-
terminus of the protein. The immunodominant region
of MAGE-A1 was found in the middle of the protein
sequence, and the corresponding regions of GPC-3
and NY-ESO-1 were located at the respective C-
termini. Interestingly, the observed profiles were simi-
lar between PBMC, IHL, and TIL, indicating that the
same peptides were recognized across different com-
partments in individual patients (Fig. 4D).
Next, we set out to identify the exact epitopes rec-
ognized by TAA-specific CD81 T cells in patients
with HCC. Although several specific epitopes have
been described for the TAA analyzed in this study
(Fig. 4D, black arrows), only a few of the correspond-
ing overlapping peptides triggered responses in our
cohort. Furthermore, some patients with responses to
those peptides did not carry the appropriate HLA-
alleles. Responses against overlapping peptides that
contained previously identified epitopes are summar-
ized in Supporting Table 3.
To identify novel epitopes, we looked for an enrich-
ment of certain HLA-alleles, if four or more patients
had CD81 T-cell responses directed against one indi-
vidual peptide (Supporting Table 3). Subsequently, in
silico epitope prediction was used to characterize
potential epitope candidates. By testing the predicted
epitopes in patients carrying the respective HLA-
alleles, we identified three novel CD81 T-cell epitopes
(Fig. 4D, gray arrows). These epitopes are summarized
in Supporting Table 3 and exemplary dot plots are
shown in Supporting Fig. 2. One epitope was located
in the immunodominant region of GPC-3, while the
other two were found in subdominant regions of
GPC-3 and NY-ESO-1, respectively.
Fig. 3. Correlation between TAA-specific CD81 T-cell responses and
patient survival. PFS data are shown for a total of 76 HCC patients.
Median PFS was 177 days in patients without and 279 days in
patients with detectable TAA-specific CD81 T-cell responses in any of
the compartments. Vertical lines indicate censored events. Survival
curves were compared by log-rank test.
Table 2. Multivariate Survival Analysis
Parameter P Hazard ratio 95% confidence interval
BCLC stage
0 0.015
A 0.268 2.403 0.590-11.348
B 0.352 2.127 0.433-10.439
C 0.011 10.217 1.706-61.187
Cirrhosis 0.006 3.556 1.433-8.827
Treatment (PFS)
TACE 0.320
RFTA 0.973 0.000 0.000-1.259 3 10266
resection 0.031 0.376 0.155-0.914
sorafenib 0.770 0.769 0.132-4.466
RFTA1TACE 0.990 1.016 0.086-11.939
Prior treatment
none 0.028
TACE 0.915 1.050 0.430-2.565
RFTA 0.204 0.210 0.019-2.331
resection 0.089 0.302 0.076-1.201
TACE1resection 0.124 2.283 0.798-6.535
TACE1RFTA 0.010 0.094 0.016-0.561
PEI 0.974 27051.681 0.000-1.372 3 10275
TACE1sorafenib 0.170 5.313 0.489-57.726
TAA recognized
0 0.024
1 0.022 0.293 0.102-0.838
2 0.004 0.172 0.053-0.565
3 0.294 0.433 0.091-2.068
4 0.112 0.157 0.016-1.544
A multivariate Cox proportional hazards model was generated for analysis of
progression-free survival (PFS). This model included data on Barcelona Clinic
Liver Cancer (BCLC) stage, treatment received at the start of the PFS interval,
treatment received prior to inclusion, liver cirrhosis and the number of tumor-
associated antigens (TAA) triggering CD81 T-cell responses in a total of 73
patients with complete datasets (Supporting Table 2). These values were either
found to correlate with PFS by univariate analysis (BCLC stage, cirrhosis, treat-
ment at start of PFS and number of TAA recognized; data not shown and Sup-
porting Fig. 1) or they correlated with TAA-specific CD81 T-cell responses
(treatment prior to inclusion, BCLC stage; Fig. 1). Due to the restraints of cohort
size, this analysis was limited to those five parameters. P-value, hazard ratio,
and its 95% confidence interval for the individual parameters are shown. BCLC
stages: 0, very early; A, early; B, intermediate; C, advanced; TACE: transarterial
chemoembolization; RFTA: radiofrequency thermal ablation; PEI: percutaneous
ethanol injection.
1420 FLECKEN, SCHMIDT, ET AL. HEPATOLOGY, April 2014
Failure to Generate TAA-Specific CD81 T-Cell
Lines. In previous work, we failed to generate TAA-
specific CD81 T-cell lines from HCC patients after in
vitro stimulation of PBMC with AFP-derived epitopes
restricted by HLA-A*02. Although peptide-specific
production of IFN-c was detectable in antigen-
unspecifically expanded CD81 T cells stimulated with
overlapping peptides, no peptide-specific CD81 T-cell
lines capable of cytokine production could be gener-
ated.7 In this study, we tried to generate CD81 T-cell
lines specific for the epitopes identified in the screen-
ing assay (Supporting Table 3). However, we did not
observe epitope-specific production of IFN-c in any of
the CD81 T-cell lines generated, despite the use of
epitopes derived from different TAA with various
HLA-restrictions (data not shown).
Detection of Dysfunctional TAA-Specific CD81 T
Cells by Tetramer Staining. Next, we generated tet-
ramers for three epitopes to exclude the possibility
that TAA-specific CD81 T cells proliferated but
remained impaired with respect to effector functions
and therefore undetectable by intracellular cytokine
staining. For this purpose, we chose the well-
characterized immunodominant epitopes NY-
ESO-1157-165/HLA-A*02:01 and MAGE-A196-104/
HLA-A*03:01 as well as the newly identified epitope
NY-ESO-1145-153/HLA-A*02:01. This panel of tet-
ramers allowed us to compare different TAA, HLA-
restrictions, and immunodominance profiles of the
corresponding TAA regions. Furthermore, MAGE-A1
and NY-ESO-1 are aberrantly expressed and immu-
nogenic in a variety of malignancies.17 Therefore, we
Fig. 4. Comparison of CD81 T-cell responses to different TAA. TAA-specific CD81 T-cell responses from PBMC, IHL, and TIL were combined
and compared according to the TAA against which they were directed. (A) Pie chart showing the number of responses observed for each TAA.
(B) Comparison of TAA-specific CD81 T-cell response magnitudes to the different TAA. Each dot represents one peptide-specific CD81 T-cell
response. The P-value indicated is the overall heterogeneity determined by Kruskal-Wallis test; posttests did not reveal significant differences
between pairs of groups. (C) The individual combinations of TAA recognized in the patient cohort. (D) Immunodominance profiles for each TAA
showing the distribution of responses across the individual overlapping peptides. Responses in CD81 T cells derived from PBMC (black) are
shown above the x-axis; responses in CD81 T cells derived from IHL (light gray) and TIL (dark gray) are shown below the x-axis. Black arrows
mark previously described CD81 T-cell epitopes; gray arrows mark newly fine-mapped CD81 T-cell epitopes.
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included 37 patients with HCC (25 HLA-A*021,
10 HLA-A*031, and two HLA-A*021/A*031) and
in addition eight patients with melanoma (five
HLA-A*021, two HLA-A*031, and one HLA-
A*021/A*031) as controls (Table 1). Indeed, tet-
ramer1CD81 T cells were readily detectable after 2
weeks of epitope-specific expansion in 15 of 37
HCC patients (41%; Fig. 5B), even though we still
failed to detect production of IFN-c in these cell
lines (Fig. 5C,D). Representative data are shown in
Fig. 5A. In comparison, four of the eight melanoma
patients had detectable TAA-specific tetramer1CD81
T-cell populations (50%) that also failed to produce
IFN-c (Fig. 5B; data not shown).
To further characterize these cells, we next analyzed
the expression of cytotoxic effector molecules on
antigen-specifically expanded TAA-specific CD81 T
cells from HCC patients. In all cell lines CD25
expression was induced, which is a sign of CD81 T-
cell activation and thus demonstrates antigen encoun-
ter (Supporting Fig. 3). However, of the cytotoxic
mediators only expression of Fas-ligand (FasL) was
induced consistently, whereas upregulation of gran-
zyme B or perforin was only observed in single cases.
To exclude the possibility of more pervasive
immune deficits in HCC patients, we generated con-
trol CD81 T-cell lines, specific for HLA-A*02-
restricted epitopes derived from cytomegalovirus
(CMV), Epstein-Barr virus (EBV), and influenza virus
(flu). In contrast to the corresponding TAA-specific
lines, we found that virus-specific CD81 T cells
derived from HCC patients were capable of producing
Fig. 5. Direct detection of TAA-specific CD81 T cells by tetramer staining. PBMC isolated from HCC patients were cultured with CD81 T-cell
epitopes restricted by HLA-A*02 (NY-ESO-1157-165 and NY-ESO-1145-153) and HLA-A*03 (MAGE-A196-104). After 2 weeks of antigen-specific
expansion, TAA-specific CD81 T cells were enumerated with tetramers and assessed for IFN-c production after peptide stimulation. (A) Represen-
tative dotplots showing tetramer stainings of TAA-specific CD81 T-cell lines from three different patients. Numbers indicate %tetramer1/CD81 T
cells. (B) Pie charts showing the frequency of patients with detectable TAA-specific tetramer1CD81 T-cell populations after expansion. For HCC
patients (left), n5 37. For melanoma patients (right), n5 8. (C) Representative tetramer and intracellular IFN-c staining data for TAA-specific
and virus-specific CD81 T-cell lines from a patient with HCC. Numbers indicate %tetramer1/CD81 T cells and %IFN-c1/CD81 T cells, respec-
tively. (D) Comparison of TAA-specific and virus-specific CD81 T-cell lines. Frequencies of tetramer1 and IFN-c1cells among the CD81 T cells in
the culture are shown. Each dot represents a single CD81 T-cell response. The paired frequencies within TAA-specific cells were compared by
Wilcoxon matched-pair test, the others by Mann-Whitney U-test.
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IFN-c after antigen-specific expansion (Fig. 5C,D).
This was not due to a higher frequency of tet-
ramer1CD81 T cells in virus-specific CD81 T-cell
lines, since these frequencies were in a comparable
range to those of TAA-specific CD81 T-cell lines. We
furthermore analyzed the expression of the inhibitory
receptors programmed death-1 (PD-1) and T-cell
immunoglobulin and mucin-3 (Tim-3) after antigen-
specific expansion (Supporting Fig. 4A,B). In this set-
ting, virus-specific CD81 T-cell lines strongly
expressed PD-1 but not Tim-3. In contrast, TAA-
specific CD81 T-cell lines showed very heterogeneous
expression levels of both inhibitory receptors (Support-
ing Fig. 4C,D). Altogether, TAA-specific CD81 T
cells from HCC patients could be specifically
expanded in vitro but retained a striking inability to
secrete IFN-c regardless of the exact nature of the
TAA, the immunodominance of the corresponding
TAA region, or the restricting HLA-molecule.
Treg Depletion Does Not Restore CD8
1 T-Cell
Functionality. Finally, we aimed to address the possible
mechanisms that might underlie this failure of TAA-
specific CD81 T cells to produce IFN-c. Adding a block-
ing antibody against the ligand of PD-1 (PD-L1) at ini-
tiation of cultures induced a very weak but detectable
production of IFN-c in one CD81 T-cell line and a very
strong increase in proliferation in another (Supporting
Fig. 5A). However, overall it had no consistent effect.
Next, we tested the effects of IL-7 and IL-12 at initiation
of the cultures, as has been described by others.13 This
led to an increase in the frequency of TAA-specific
CD81 T cells in 5 of 10 cell lines (50%), while it had an
inverse effect in the remaining cell lines. Furthermore,
there was no effect on the functionality of TAA-specific
CD81 T cells (Supporting Fig. 5B). As regulatory T cells
(Treg) are enriched in patients with HCC and can nega-
tively affect CD81 T-cell function,18 we next asked
whether these cells were also enriched in our patient
cohort. Accordingly, we measured the frequency of Treg,
defined as CD41CD251FoxP31 cells, in PBMC, IHL,
and TIL from HCC patients (Fig. 6A). To enable com-
parison with noncancer patients, we also studied a large
cohort of controls including healthy donors and hepatitis
patients undergoing diagnostic liver biopsies (Table 1).
Treg were significantly enriched in IHL compared to
PBMC (Fig. 6B). This intrahepatic enrichment of Treg
was significantly increased in HCC patients, both in IHL
and even more so in TIL (Fig. 6B).
As Treg appeared to be a major immunosuppressive
mechanism in HCC patients, we depleted CD251
cells (Treg) from epitope-specific CD8
1 T-cell lines
prior to culture. In five out of eight cell lines (62.5%)
with detectable tetramer1CD81 T cells we observed
an increase in the frequency of tetramer1CD81 T
cells. In two cases, tetramer1CD81 T cells became
undetectable after CD251 cell depletion, presumably
due to CD25 expression on the TAA-specific CD81 T
cells ex vivo. There was no effect on the antigen-
specific production of IFN-c, as all cell lines remained
dysfunctional (Fig. 6C). Thus, Treg impaired the pro-
liferation of TAA-specific CD81 T cells in HCC
patients. However, Treg-depletion alone did not restore
TAA-specific cytokine production, suggesting that dif-
ferent or additional mechanisms are responsible for the
observed dysfunctionality of TAA-specific CD81 T
cells.
Discussion
In this study we used overlapping peptides spanning
the entirety of the AFP, GPC-3, MAGE-A1, and NY-
ESO-1 proteins to conduct a comprehensive and
unbiased analysis of immunodominant TAA-specific
CD81 T-cell responses in patients with HCC. Several
important findings emerged from our investigation.
First, antigen-specific CD81 T-cell responses
directed against all four TAA analyzed were readily
observed in more than 50% of HCC patients, signifi-
cantly greater than the corresponding frequency of
detection in healthy donors or patients with viral hepa-
titis. This is in agreement with our earlier study
focused on AFP.7 In addition, these TAA-specific
CD81 T-cell responses were more frequently detecta-
ble in patients with very early tumor stage. It is impor-
tant to note that some of these patients had undergone
prior locoregional therapy. In this setting it has been
shown that especially RFTA enhances and/or induces
TAA-specific CD81 T-cell responses in individual
patients.15,16 We show that this effect is also detectable
for patients treated with TACE. Indeed, it may con-
tribute to the observed enrichment of CD81 T-cell
responses in patients with early stage HCC and sup-
ports the view that the release of autologous TAA can
induce and/or boost TAA-specific CD81 T-cell
responses.15,16
Second, the occurrence of TAA-specific CD81 T-
cell responses in HCC patients was associated with
improved PFS. Our results suggest that TAA-specific
CD81 T-cell responses may indeed be a prognostic
factor of patient survival that appears to be independ-
ent of the potentially confounding factors of BCLC
stage and prior treatment. The mentioned association
of strong TAA-specific CD81 T-cell responses with
PFS in patients undergoing locoregional therapy
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further supports a possible protective role of such
responses.16,19 Especially the occurrence of CD81 T-
cell responses specific for multiple TAA may be benefi-
cial. Even though this aspect requires confirmation in
a larger cohort, we found significantly superior PFS in
patients with CD81 T-cell responses to one or two
TAA and a similar trend for those with responses to
three or four TAA. Furthermore, we observed only
one case of tumor progression among the four patients
with responses against all four TAA. Based on these
data, it is tempting to speculate that TAA-specific
CD81 T-cell responses may benefit patient survival by
hindering tumor growth and thus maintaining early
stage disease for longer periods of time.
Third, CD81 T-cell responses specific for individual
TAA displayed clear immunodominance patterns.
Immunodominant regions are preferential targets for
T-cell responses because they are immunogenic in
most individuals within a cohort.20 Indeed, even in
our HLA-independent assay, we observed that most
CD81 T-cell responses targeted single immunodomi-
nant regions within a given TAA. Despite our inability
to establish a clear immunodominance profile for AFP
in a previous study,7 we were able to identify an
immunodominant region at the N-terminus by using
the larger cohort studied here. In addition, we could
identify immunodominant regions in the middle of
MAGE-A1 and at the C-termini of GPC-3 and NY-
ESO-1. It is important to note, however, that the pro-
tein regions identified by overlapping peptides in our
approach may contain several CD81 T-cell epitopes
restricted by different HLA-molecules. In this study,
almost a third of the overlapping peptides that trig-
gered responses contained previously described CD81
T-cell epitopes. For example, the immunodominant
region of NY-ESO-1 contains the epitope NY-ESO-
Fig. 6. Presence and activity of Treg in patients with HCC. Physical and functional analyses of Treg were conducted using flow cytometry and
magnetic bead depletion, respectively. (A) Representative dotplots showing flow cytometric quantification of Treg in PBMC, IHL, and TIL from a
patient with HCC. Cells were gated on CD41 events. CD25 and FoxP3 expression are displayed. Numbers indicate percentage of Treg character-
ized as CD251FoxP31 cells among CD41 T cells. (B) Treg frequencies as in (A) in the indicated compartments of patients with HCC, with chronic
viral hepatitis or of controls and patients with other forms of hepatitis. Each dot represents one patient; lines indicate mean values. Frequencies
were compared by one-way analysis of variance (ANOVA). Next to the P-values indicated, frequencies of HCC-IHL and HCC-TIL were significantly
higher than those of all the other groups (P< 0.05 compared to HBV-IHL and P< 0.001 compared to all other groups). (C) Effect of Treg-deple-
tion on TAA-specific CD81 T-cell proliferation and function. Treg were removed from PBMC by depletion of CD25
1 cells using magnetic beads
prior to culture. Tetramer-frequencies (black squares) and production of IFN-c (white circles) are indicated.
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1157-165 which is frequently recognized by HLA-
A*021 HCC patients.12 However, given that only
58% of patients with a response to the corresponding
NY-ESO-1-peptide were HLA-A*021, it is likely that
this region of NY-ESO-1 contains additional,
unknown CD81 T-cell epitopes restricted by other
HLA-molecules. Of note, we were able to characterize
three novel CD81 T-cell epitopes within the immuno-
dominant region of GPC-3 and within subdominant
regions of GPC-3 and NY-ESO-1, respectively. Previ-
ous studies comparing different TAA focused on epi-
topes restricted by single HLA-molecules. For HLA-
A*02, the NY-ESO-1157-165 epitope is thought to be
immunodominant compared to similarly restricted epi-
topes derived from other TAA.12 However, for HLA-
A*24, no single epitope or TAA was found to be
immunodominant.13 These results underline the
importance of HLA-independent analyses. Indeed, to
our knowledge, this is the first study that compares
TAA-specific CD81 T-cell responses in HCC patients
irrespective of HLA-restriction. Accordingly, our results
have important implications for immunotherapy and
tumor vaccine design.
Fourth, functional TAA-specific CD81 T cells of
HCC patients cannot readily be expanded in vitro.
Indeed, we could not detect peptide-specific produc-
tion of IFN-c after antigen-specific culture of CD81
T cells with epitopes derived from MAGE-A1 and
NY-ESO-1. These results are in line with previous
studies showing that CD81 T-cell lines specific for
either AFP or GPC-3 fail to produce IFN-c.7,8 How-
ever, when we used tetramers representing epitopes
derived from MAGE-A1 and NY-ESO-1 to detect
TAA-specific CD81 T cells independent of their func-
tionality, we were able to find those cells in more than
50% of HCC patients. The presence of tetramer-
binding TAA-specific CD81 T cells after in vitro
expansion, but not ex vivo (data not shown), indicates
proliferation of a very low frequency precursor popula-
tion. Thus, cytokine production rather than prolifera-
tion may be defective in HCC-specific CD81 T cells.
This is consistent with other studies reporting dysfunc-
tional TAA-specific CD81 T cells.8,9,12 It is also a par-
ticularly important observation given that the
induction of TAA-specific IFN-c production by T cells
has been proposed as a major determinant of success
in therapeutic tumor vaccine trials targeting other
malignancies.2 Furthermore, we found a limited
expression of cytotoxic mediators by the expanded
TAA-specific CD81 T cells. While FasL was produced,
expression of perforin or granzyme B was often not
detectable. Indeed, a reduced ex vivo expression of per-
forin and granzyme B among CD81 TIL in HCC
patients has been described.18 However, in contrast to
HCV-specific CD81 T cells that also lack expression
of perforin ex vivo, TAA-specific CD81 T cells were
mostly incapable of up-regulating perforin after
antigen-specific expansion.21
Several mechanisms may explain this dysfunctional
phenotype of TAA-specific CD81 T cells. First, the
immunosuppressive tumor microenvironment may be
responsible, for example, by the production of immu-
noregulatory cytokines or by the local action of inhibi-
tory receptors such as PD-1, as described recently in a
mouse model.22,23 This is in line with our observation
of significantly reduced magnitudes of TAA-specific
CD81 T-cell responses at the tumor site compared to
the periphery. Furthermore, we detected heterogeneous
expression of the inhibitory receptors PD-1 and Tim-3
on antigen-specifically expanded TAA-specific CD81 T
cells and effects of PD-L1 blockade on individual cell
lines that were in one case even sufficient to restore the
production of IFN-c. Second, TAA-specific T-cell recep-
tors (TCRs) may have very low affinities for peptide-
HLA complexes relative to virus-specific TCRs.24,25
Consequently, physiological stimulation of TAA-specific
CD81 T cells with the cognate peptide may deliver a
signal that is too weak to restore functionality. This
may also explain why IFN-c production was preserved
after antigen-independent expansion, which relies on
direct crosslinking of CD3f rather than TCR engage-
ment. Third, a lack of CD41 T cell help and the
action of Treg may also contribute to the observed func-
tional defects.18,26 Indeed, the important role of Treg in
the immunobiology of HCC is suggested by the enrich-
ment of these cells in HCC patients, a negative associa-
tion with patient survival, and the unmasking of AFP-
specific CD41 T-cell responses after in vivo depletion
of Treg in HCC patients.
18,27 Of note, we also observed
Treg enrichment in tumor and liver tissue in HCC
patients. In addition, the depletion of Treg prior to
antigen-specific stimulation increased the proliferation
of TAA-specific CD81 T cells in 60% of cases. How-
ever, these expanded TAA-specific CD81 T cells still
failed to produce IFN-c, suggesting that different or
additional mechanisms beyond Treg-mediated effects
may contribute to the lack of cytokine production
observed in our study and that addressing single path-
ways contributing to T-cell failure may be insufficient
to restore CD81 T-cell functionality.
In summary, we have shown that immunodominant
TAA-specific CD81 T-cell responses in HCC patients
are spread across multiple antigens and associated with
patient survival. However, the expansion of functional
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TAA-specific CD81 T cells from patients with HCC
is difficult due to functional impairments. A better
understanding of the mechanisms that underlie this
dysfunctionality is required to expedite the develop-
ment of effective immunotherapies for HCC.
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